Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

Earlier this month, Pfizer filed a lawsuit (HP-2022-000016) in the Royal Courts of Justice in London, seeking to invalidate three GSK patients covering its RSVPreF3 shot, according to a report on ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

LONDON, Oct 7 (Reuters) - Pfizer (PFE.N), opens new tab on Monday won a bid in a London court to invalidate two of GSK's (GSK.L), opens new tab patents relating to a respiratory syncytial virus ...

The shots are important for both Pfizer and GSK as they look to build new franchises before top-selling drugs face generic competition later this decade. Pfizer is also contending with activist ...

On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK said it acquired an experimental therapy from Chimagen Biosciences that it aims to test in different forms of lupus, and ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

Pfizer returned $7.1 billion to shareholders as cash dividends in the first nine months of 2024. During the same period, the company received roughly $6.9 billion of net cash proceeds from the sale of ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.